GLP-1 Comparison · May 2, 2026 · Prices Verified

Mounjaro vs Wegovy: 2026 Verdict, Real Costs & the Comparison Most People Get Wrong

Published: May 2, 2026

Written by The RX Index Editorial Team

Last verified: May 2, 2026 · FDA labels checked via DailyMed · Affiliate disclosure

Bottom line — verified May 2, 2026

Mounjaro and Wegovy are both highly effective GLP-1 medications, but they’re not really competing for the same patient. Wegovy (semaglutide) is FDA-approved for chronic weight management; for reducing the risk of major adverse cardiovascular events in adults with established CVD and obesity or overweight; and — injection only — for noncirrhotic MASH with moderate-to-advanced liver fibrosis (accelerated approval). Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only.

In the SURMOUNT-5 head-to-head trial in adults with obesity (no diabetes), tirzepatide produced about 20.2% mean weight loss at 72 weeks vs 13.7% on Wegovy 2.4 mg. The newer Wegovy HD (7.2 mg) reached about 20.7% in the separate STEP UP trial — not a head-to-head, but meaningful context.

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. The RX Index may earn a commission if you use some provider links on this page. Our recommendations are based on FDA labeling, verified pricing, access, and reader fit — not affiliate payouts.

Don’t pay cash before you check coverage. Ro prescribes Wegovy (pill and pen) and Zepbound at NovoCare and LillyDirect cash-pay prices, and their insurance concierge handles your prior-authorization paperwork at no extra cost. Ro Body membership is $39 for the first month, then as low as $74/month with annual prepay — GLP-1 medication cost is charged separately.

Check your GLP-1 coverage on Ro — free, ~5 minutes →

Quick verdict — the 30-second answer

Mounjaro vs Wegovy at a glance: the 2026 comparison that actually matters

We built this table by pulling the FDA prescribing information for both drugs from DailyMed, the SURMOUNT-5 trial data published in The New England Journal of Medicine, and current cash-pay pricing from NovoCare, LillyDirect, and the major telehealth platforms. We checked it the day this page was published. The next sections explain every row in plain English.

The Verified 2026 Mounjaro vs Wegovy Decision Matrix

Sources: FDA prescribing information (Mounjaro, Wegovy injection, Wegovy tablet) via DailyMed; SURMOUNT-5 trial, NEJM, May 2025; STEP UP trial; NovoCare.com; LillyDirect.com; Lilly pricing info pages. Verified May 2, 2026.

Is Mounjaro FDA-approved for weight loss?

This is the question that decides what you should actually ask your doctor for. Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses, made by the same company (Eli Lilly). The only meaningful difference is the FDA label.

• Mounjaro: approved for type 2 diabetes
• Zepbound: approved for chronic weight management and obstructive sleep apnea in adults with obesity

If you ask a clinician for Mounjaro and you don’t have diabetes, two things tend to happen. Some clinicians will write the prescription off-label. Others won’t, because they know your insurance will deny it. Either way, you’ve created an avoidable problem. Asking for Zepbound puts the right brand name on the right label — and that’s often the difference between a $25 copay and a $1,000+ retail bill.

Why “Mounjaro vs Wegovy” is the wrong question for most weight-loss searchers

Here’s the trust-first thing we’ll say up front: the search term most people are typing is slightly off, and the top-ranking pages mostly don’t tell you that.

It’s not your fault. Mounjaro has the bigger brand name. It got famous first. The headlines you saw (“tirzepatide beats semaglutide for weight loss”) came from a study that technically tested Zepbound vs Wegovy — but the news called it “Mounjaro vs Wegovy” because more people recognize Mounjaro. So the wrong name stuck.

Here’s what’s actually going on:

• Tirzepatide is the chemical name. Eli Lilly sells it under two brand names: Mounjaro (for diabetes) and Zepbound (for weight loss).
• Semaglutide is the chemical name. Novo Nordisk sells it under two brand names: Ozempic (for diabetes) and Wegovy (for weight loss).

Same molecule, different brand name, different label. The label is what insurance pays attention to. If you ask for Mounjaro for weight loss without diabetes, your insurance almost certainly says no — because that’s “off-label” use. If you ask for Zepbound for weight loss, you have a real shot at coverage because that’s exactly what it’s approved for.

That’s why this matters: getting the right brand name on your prescription is often the difference between paying $25 a month and paying $1,000+ a month.

We’ll keep using “Mounjaro vs Wegovy” through the rest of this guide because that’s how the question gets asked. But every time you see “Mounjaro” in a weight-loss context, mentally swap in “Zepbound” — that’s the version with the right label. We have a separate page on Zepbound vs Wegovy if that’s the comparison you actually need.

SURMOUNT-5: what the head-to-head trial actually showed

Let’s actually look at the numbers, because this is where most articles either oversimplify or get it wrong.

What SURMOUNT-5 found

The trial randomly assigned 751 adults with obesity (and at least one weight-related condition like high blood pressure or sleep apnea) to either tirzepatide or semaglutide for 72 weeks. Nobody had type 2 diabetes. Patients took the maximum dose they could tolerate.

After 72 weeks:

• Tirzepatide group: average weight loss of 20.2% — about 50.3 pounds for a 250-pound person.
• Semaglutide group: average weight loss of 13.7% — about 33.1 pounds for a 250-pound person.
• Tirzepatide produced 47% more relative weight loss than semaglutide over the same time period.
• Almost 1 in 3 (31.6%) of the tirzepatide group lost 25% or more of their body weight, vs 16.1% of the semaglutide group.

People on semaglutide were about twice as likely to drop out of the trial because of GI side effects — 5.6% vs 2.7% for tirzepatide.

Source: Aronne et al., “Tirzepatide vs Semaglutide for Treatment of Obesity,” New England Journal of Medicine, May 2025.

Two huge caveats

We’re not going to bury these.

Caveat #1: The trial was funded and designed by Eli Lilly, the company that makes tirzepatide. It was peer-reviewed and published in a top journal, so the results are real. But Lilly chose the design — and the design tested Wegovy at 2.4 mg, the highest dose available when the trial started.

Caveat #2: The trial was open-label, meaning patients and doctors knew which drug they were getting. Open-label trials are common, but they can shift expectations and behavior in ways that affect outcomes.

Wegovy HD changes the picture — but doesn’t erase SURMOUNT-5

In March 2026, the FDA approved a higher 7.2 mg dose of Wegovy (called Wegovy HD) based on the separate STEP UP trial. The approval is for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction.

• Wegovy HD (7.2 mg) in STEP UP: average weight loss of 20.7% at 72 weeks (treatment-policy estimand, Novo Nordisk publication).
• Wegovy 2.4 mg in STEP UP: about 17%.

That STEP UP result is much closer to what tirzepatide produced in SURMOUNT-5. But here’s the honest read: SURMOUNT-5 and STEP UP are different trials with different populations and different statistical methods. You can’t compare them like a head-to-head. Wegovy HD wasn’t tested against tirzepatide in any trial. So saying “Wegovy HD now equals tirzepatide” overstates what the data supports. Saying “Wegovy HD substantially closes the gap on the older comparison” is fair.

Cross-trial guardrail: what you can and can’t conclude

What real-world data shows

Trial data tells you what happens when patients are carefully selected and supported. Real-world data tells you what happens out in the wild.

A 2024 JAMA Internal Medicine cohort identified 41,222 adults and analyzed 18,386 propensity-score-matched patients initiating tirzepatide or semaglutide for type 2 diabetes. Patients on tirzepatide were more likely to hit 5%, 10%, and 15% weight-loss milestones than those on semaglutide. Discontinuation was common in both groups, and rates of GI side effects were similar.

Translation: in real life, both drugs work better than diet and exercise alone, both can be hard to stay on, and tirzepatide tends to produce somewhat better numbers when patients stick with it.

Mounjaro vs Wegovy for type 2 diabetes

If you’re searching this comparison because of diabetes (not weight loss), the answer flips.

Mounjaro is built for blood sugar. The trials behind it (the SURPASS program) showed it lowered A1C more than the diabetes-labeled version of semaglutide (Ozempic) at every dose tested. It’s also FDA-approved for kids 10 and older with type 2 diabetes — Wegovy is not.

If your doctor is choosing a GLP-1 to manage your diabetes:

• Mounjaro is one of the strongest options on the market for both glucose control and weight reduction.
• Wegovy is not the right comparison drug — the diabetes version of semaglutide is Ozempic. We have a separate guide on Mounjaro vs Ozempic if that’s the real question.

A note on hypoglycemia

Mounjaro alone rarely causes low blood sugar. But if you’re already on insulin or a medication called a sulfonylurea (like glipizide or glimepiride), adding Mounjaro can drive your blood sugar too low. The label specifically warns about this. Your doctor will likely lower your insulin dose when you start.

If you have diabetes, don’t make this decision based on a comparison article — including this one. Bring it to whoever manages your diabetes. The question to ask: “Given my A1C, weight, and other meds, is Mounjaro the right next step?”

How Mounjaro and Wegovy actually work

Your gut releases hormones after you eat. Some of them tell your brain to stop eating. Others tell your pancreas to release insulin. GLP-1 (glucagon-like peptide-1) is one of those hormones. GIP (glucose-dependent insulinotropic polypeptide) is another.

GLP-1 medications copy what your body already does — but more strongly and for longer.

Wegovy is GLP-1 only

Wegovy mimics GLP-1. That hormone:

• Sends “I’m full” signals to your brain
• Slows how fast food leaves your stomach (so you stay full longer)
• Helps your pancreas release insulin when blood sugar rises
• Reduces “food noise” — the mental chatter about what to eat next

Mounjaro is GLP-1 + GIP (dual action)

Mounjaro mimics both GLP-1 and GIP. The GIP piece adds a second mechanism: it helps your body process insulin and may improve how fat tissue works. Most researchers think this is why tirzepatide tends to produce somewhat bigger weight-loss numbers in trials.

The honest summary: dual action sounds better on paper, and the trial data supports that. But mechanism doesn’t tell the whole story. Some people lose more weight on semaglutide than on tirzepatide. Some people tolerate one and not the other. The “stronger drug” isn’t always the right drug for you.

What you’ll actually pay in 2026: Mounjaro vs Wegovy real prices

This is the section that surprises most readers. The cash-pay world for these drugs changed completely in late 2025 and early 2026.

Wegovy: the cheapest FDA-approved branded path right now

Novo Nordisk runs a direct-to-patient program called NovoCare Pharmacy. Through it (verified May 2, 2026):

• Wegovy pill 1.5 mg and 4 mg: $149/month — the 4 mg offer is listed through August 31, 2026, then $199/month
• Wegovy pill 9 mg and 25 mg: $299/month
• Wegovy injection 0.25 mg or 0.5 mg (intro for new patients): $199/month for the first two monthly fills, available through June 30, 2026
• Wegovy injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg: $349/month standard
• Wegovy HD 7.2 mg: $399/month
• Wegovy list price (full retail at a pharmacy): about $1,349/month

Source: NovoCare.com, verified May 2, 2026.

Mounjaro: no manufacturer cash-pay equivalent yet

Eli Lilly currently does not offer a NovoCare-style direct cash-pay program for Mounjaro. Lilly does run one for Zepbound (the weight-loss version of tirzepatide), but Mounjaro is still in the older pricing world.

What that looks like (verified May 2, 2026):

• Mounjaro list price: $1,112.16 per 28-day fill, before insurance, pharmacy charges, discounts, or savings-card eligibility
• Mounjaro with commercial insurance + Lilly Mounjaro Savings Card: as low as $25/month, but only with a prescription for an approved use consistent with FDA-approved labeling (i.e., type 2 diabetes)
• Mounjaro with commercial drug insurance that doesn’t cover Mounjaro + savings card: as low as $499 for a 1-month fill, again only with a prescription for an approved use consistent with FDA-approved labeling
• Mounjaro without commercial insurance: typically close to list price at retail pharmacies; the savings card does not work

Source: startlilly.com/mounjaro and pricinginfo.lilly.com, verified May 2, 2026.

Zepbound (the weight-loss version of tirzepatide) cash prices

If your real question is “I want tirzepatide and I can’t get insurance to cover Mounjaro,” Zepbound is your move. Eli Lilly sells Zepbound through a program called LillyDirect, and Ro carries Zepbound KwikPen at matching cash-pay prices:

• 2.5 mg starter dose: $299/month
• 5 mg dose: $399/month
• Zepbound KwikPen 7.5 mg, 10 mg, 12.5 mg, 15 mg: $449/month for eligible refills completed within 45 days
• Zepbound single-dose vials are available separately through LillyDirect with their own pricing terms

Source: LillyDirect.com and Ro Zepbound KwikPen announcement, verified May 2, 2026.

The $25 coupon trap (read this before you call your pharmacy)

The “Mounjaro for $25” headline you’ve probably seen comes with strings most articles don’t explain.

That $25 price applies only if all three of these are true:

1. You have commercial drug insurance (not Medicare, Medicaid, TRICARE, or VA)
2. Your insurance plan covers Mounjaro on its formulary
3. Your prescription is for an FDA-approved use consistent with the Mounjaro label (type 2 diabetes — not weight loss)

If your commercial insurance doesn’t cover Mounjaro, the savings card may drop the price to as low as $499/month — but the same FDA-approved-use rule still applies. If you have Medicare or Medicaid, the savings card doesn’t work for you at all under federal anti-kickback rules. We have a full guide on Medicare GLP-1 coverage for that situation.

Provider-Stated vs Verified pricing (transparency table)

This is what we actually checked.

Will my insurance cover Mounjaro or Wegovy?

Insurance coverage is where this comparison gets either really easy or really painful. The simple rule:

Insurance pays for medications used the way the FDA approved them. Off-label use is a fight.

The typical coverage picture

What is “prior authorization” and how do you survive it?

Prior authorization (PA) is when your insurance plan says: “Before we’ll cover this drug, we want your doctor to prove you actually need it.”

A typical PA for Wegovy might require:

• A documented BMI of 30+ (or 27+ with a related condition)
• Notes that you’ve tried diet and exercise without success
• Lab work
• Sometimes documentation that you’ve tried other medications first (“step therapy”)

The paperwork is the worst part. Many prescribing doctors hate it. Some won’t fight a denial because their day is already full.

This is where telehealth platforms with insurance concierges shine. Ro has a dedicated team that handles your prior authorization paperwork at no extra cost — you don’t fill out any forms, you don’t fight your insurance, you don’t even pick up a phone. Ro says its insurance concierge works with insurers to determine GLP-1 coverage and shows you a coverage report including prior-authorization details before you commit.

Federal employees and unique plans

If you have Federal Employee Health Benefits (FEHB), Ro can still help coordinate coverage. If you have a high-deductible plan with HSA/FSA, both Mounjaro and Wegovy are eligible expenses (which gives you about a 20–30% effective savings depending on your tax bracket).

Medicare GLP-1 Bridge: what’s actually covered

The Medicare GLP-1 Bridge is a CMS demonstration program scheduled to run from July 1, 2026, through December 31, 2027. CMS currently lists these as eligible Bridge drugs when used to reduce excess body weight and maintain weight reduction:

• Foundayo
• Wegovy injection
• Wegovy tablets
• Zepbound KwikPen (the single-dose vial and single-dose pen are not included)

Mounjaro is not on the Bridge list because the program is for weight-loss use, and Mounjaro is FDA-approved for diabetes.

Eligible Medicare Part D beneficiaries who meet CMS prior-authorization criteria may pay a $50 copay for Bridge drugs. The $50 copay is not automatic for every Medicare beneficiary. We have a full Medicare GLP-1 Bridge guide with the eligibility checklist.

Mounjaro vs Wegovy side effects: what changes most

Both drugs work by slowing your stomach down and changing your appetite signals. That means the side-effect profile is mostly about your digestive system.

Common side effects (both medications)

Most patients experience at least some of these, especially during the first 12 weeks while titrating up:

• Nausea (most common)
• Diarrhea
• Vomiting
• Constipation
• Stomach pain or discomfort
• Reduced appetite (which is, weirdly, the goal — but it can feel uncomfortable)
• Heartburn / acid reflux
• Burping
• Tiredness or fatigue

Most of these fade or become manageable after about 8–12 weeks. The strongest predictor of staying on the medication: starting at the lowest dose and titrating up slowly. Doctors who push patients up too fast lose more patients to side effects.

Where the two drugs differ on side effects

In the SURMOUNT-5 head-to-head trial, GI side effects severe enough to make patients drop out were about twice as common with semaglutide as with tirzepatide — 5.6% vs 2.7%. That’s not nothing. If you’ve had a hard time tolerating semaglutide in the past, tirzepatide may sit better with you.

That said, individual responses vary a lot. We’ve seen patients who couldn’t tolerate one and did fine on the other in either direction.

Serious warnings (both drugs)

Both Mounjaro and Wegovy carry a boxed warning — the FDA’s strongest — about thyroid C-cell tumors. The warning comes from rat studies. We don’t have evidence this happens in humans, but as a precaution, neither drug should be used by anyone with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Other serious risks listed on both labels:

• Pancreatitis (inflammation of the pancreas — severe stomach pain that won’t go away)
• Gallbladder disease (more common with rapid weight loss)
• Severe GI reactions
• Acute kidney injury (usually from dehydration caused by vomiting/diarrhea)
• Diabetic retinopathy complications (specific to people who already have it)
• Hypersensitivity reactions

Side effect specific to Mounjaro: oral birth control

Mounjaro can make oral birth control less effective. This is in the label and most articles miss it. Because Mounjaro slows stomach emptying, it can change how your body absorbs oral hormonal contraceptives. The FDA label specifically advises:

Switch to a non-oral birth control method, or add a barrier method (like condoms) for 4 weeks after starting Mounjaro and for 4 weeks after every dose increase.

If you’re on the pill and considering Mounjaro, talk to your doctor about an IUD, implant, or shot before you start. This is genuinely important.

Side effects specific to Wegovy

Wegovy and pregnancy. The FDA label says Wegovy may cause fetal harm and should be discontinued when pregnancy is recognized. Because semaglutide stays in your body for weeks, the label recommends discontinuing at least 2 months before a planned pregnancy.

Vision concern (NAION). In June 2025, the European Medicines Agency’s PRAC committee concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a “very rare” side effect of semaglutide medicines, including Wegovy, Ozempic, and Rybelsus, recommending the product information be updated. WHO summarized the conclusion as potentially affecting up to 1 in 10,000 users. If you experience sudden vision changes on Wegovy, contact your doctor right away.

We cover all of this and more in our GLP-1 safety guide.

Dosing schedules: Mounjaro vs Wegovy week by week

Both medications follow the same playbook: start low, go slow, increase monthly. Your stomach needs time to adjust. Skipping doses or jumping levels too fast is the #1 cause of nausea so bad people quit.

Mounjaro titration schedule

A clinician can stop you at any maintenance dose (5, 10, or 15 mg) if you’re hitting your goals or side effects flare. You don’t have to escalate to 15 mg.

Wegovy injection titration schedule

The Wegovy pill (oral semaglutide for weight loss) has a different schedule because it’s daily, not weekly, and titrates 1.5 mg → 4 mg → 9 mg → 25 mg. We cover that in our Wegovy pill vs injection guide.

What to expect during dose changes

The first 1–2 weeks after each dose increase tend to be the worst. Nausea picks up. Some people lose more weight that week. Then your body adjusts and you stabilize for the rest of the month.

Tips that help most patients:

• Inject the same day each week
• Eat smaller meals, especially right after dose increases
• Drink more water than feels normal (dehydration makes everything worse)
• Avoid greasy or sugary foods for the first day or two after a dose change

Wegovy pill vs Mounjaro injection: when does the pill win?

This is one of the cleanest decisions on this whole page.

If you genuinely cannot or will not inject yourself, you don’t really have a “Mounjaro vs Wegovy” decision at all. You have a “Wegovy pill vs nothing” decision. Mounjaro doesn’t make a pill.

The Wegovy pill, which launched in January 2026 after FDA approval in December 2025, has these advantages over the injection:

• No needles
• Cheaper cash price ($149–$299/month vs $199–$399/month)
• Stores at room temperature (the pen needs refrigeration)
• Easier for travel

And these tradeoffs:

• Strict timing rules. Take it on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking, or taking other meds. If you skip the timing window, the pill doesn’t work right.
• Slightly less weight loss in trials at standard maintenance doses
• Daily, not weekly — you have to remember every morning

The pill also doesn’t have the higher 7.2 mg HD option that the injection has.

For most adults who don’t mind a weekly injection, the pen is the stronger overall pick. For people whose needle aversion is keeping them from starting at all, the pill is clearly the better choice — and it’s far better than not starting.

We have a complete breakdown in our Wegovy pill vs injection guide.

Switching between Mounjaro and Wegovy

People search “switch from Mounjaro to Wegovy” for a few common reasons. Each has a different right answer.

Reason 1: “My insurance stopped covering Mounjaro”

This is by far the most common scenario. If you’re on Mounjaro for weight loss and your insurance reviews and denies coverage (because it was always off-label), you have three paths:

• Switch to Wegovy if your insurance covers it for weight loss
• Switch to Zepbound if your insurance covers tirzepatide-based weight loss specifically
• Pay cash for whichever fits — Wegovy pill is the cheapest FDA-approved cash-pay option right now

A coverage change is also a moment to ask your doctor whether the original Mounjaro prescription was the right one. If you don’t have diabetes, Zepbound was probably the right brand all along.

Reason 2: “I plateaued on one drug and want to try the other”

This happens. Bodies adapt. If you’ve been at maintenance dose for 6+ months and your weight stalled, your doctor might recommend switching mechanisms — from semaglutide (one hormone) to tirzepatide (two), or vice versa.

There’s no formal “switching protocol” between the two drugs because they’re chemically different. Most clinicians:

1. Stop the first medication completely
2. Wait at least 1–2 weeks (the washout)
3. Start the new medication at its lowest dose
4. Titrate up like a brand-new patient

Don’t try to “convert” doses on your own. There’s no clean equivalent — for example, 5 mg of tirzepatide isn’t the same strength as 0.5 mg of semaglutide. Your doctor will pick a starting dose based on side-effect history and goals.

Reason 3: “I want to try the ‘stronger’ drug”

If you’re on Wegovy and you’ve heard tirzepatide produces more weight loss, the conversation to have isn’t about Mounjaro — it’s about Zepbound. Asking for Mounjaro for weight loss puts you back in the off-label coverage problem. Zepbound has the same active ingredient and the right FDA label.

A safety note on combining

Don’t take Mounjaro and Wegovy at the same time. Wegovy’s labeling says concomitant use with other semaglutide-containing products or other GLP-1 receptor agonists is not recommended. Don’t combine GLP-1 medications unless a licensed clinician specifically directs it.

Mounjaro vs Wegovy vs Zepbound vs Ozempic: the full FDA-approved landscape

This table sorts out the four most-searched brand names — and the new fifth one.

The two simple rules

1. For weight loss without diabetes: the FDA-approved options are Wegovy, Zepbound, and Foundayo. Mounjaro and Ozempic are off-label.
2. For type 2 diabetes: Mounjaro and Ozempic are FDA-approved. Wegovy and Zepbound aren’t approved for diabetes (though Wegovy can be prescribed for cardiovascular risk and for the labeled MASH indication if those apply).

If your doctor is prescribing for two conditions at once (diabetes + obesity, or obesity + heart disease, or obesity + MASH), the picture gets more nuanced. That’s a conversation, not a comparison-article answer.

Who should choose Wegovy?

Wegovy makes sense as your first call when:

• You want weight loss and don’t have diabetes. It’s FDA-approved for this; Mounjaro isn’t.
• You have established cardiovascular disease + overweight or obesity. The SELECT trial data supports the FDA-approved indication to reduce risk of major adverse cardiovascular events in this group. No other GLP-1 in this comparison has this label.
• You have noncirrhotic MASH with moderate-to-advanced liver fibrosis. Wegovy injection received FDA accelerated approval for this indication in August 2025. We have a separate guide on the best GLP-1 for fatty liver.
• You’re an adolescent (12+) or have one in the family. Wegovy has a pediatric approval for obesity in this age group; Mounjaro doesn’t.
• You want a pill option. Wegovy is the only GLP-1 in this comparison available as a daily pill.
• You’re paying cash and want a low FDA-approved branded starting price. As of May 2, 2026, Wegovy pill 1.5 mg or 4 mg is $149/month through NovoCare.

Wegovy might NOT be your best fit if:

• You have type 2 diabetes (Mounjaro is the more relevant medication)
• You specifically want tirzepatide for weight loss (Zepbound is the FDA-approved match)
• You can’t tolerate semaglutide’s GI profile (consider switching to tirzepatide via Zepbound)
• You’re planning a pregnancy in the next 2–3 months

Who should ask about Mounjaro?

You’re a Mounjaro candidate if:

• You have type 2 diabetes
• Your doctor is choosing a GLP-1 to improve blood sugar
• Weight loss matters to you but isn’t the primary diagnosis
• Your insurance covers Mounjaro (most commercial plans do for diabetes, often with prior authorization)
• You qualify for the Lilly Mounjaro Savings Card (as low as $25/month with commercial coverage and a prescription for FDA-approved use)

You’re probably not a Mounjaro candidate if:

• You don’t have diabetes and the only reason you wanted Mounjaro is weight loss
• Your insurance won’t cover it (you’ll pay close to list price — $1,112.16 per fill)
• You’re a candidate for the new Medicare GLP-1 Bridge (which favors Wegovy and Zepbound)

If you’re in this second group, the redirect is simple: ask your prescriber about Zepbound if you wanted tirzepatide, or Wegovy if you’re open to either molecule.

Who should compare Zepbound instead?

You should be reading “Zepbound vs Wegovy” instead of “Mounjaro vs Wegovy” if:

• You don’t have type 2 diabetes
• You want tirzepatide for weight loss specifically
• The SURMOUNT-5 numbers are why you’re here
• You have moderate-to-severe obstructive sleep apnea + obesity
• Your insurance won’t cover Mounjaro for weight loss but might cover Zepbound

The honest summary: for non-diabetic weight-loss seekers, the SURMOUNT-5 trial that everyone calls “Mounjaro vs Wegovy” is really “Zepbound’s molecule vs Wegovy.” The 20.2% vs 13.7% number applies to tirzepatide vs semaglutide as drugs — and the way you legally and affordably get tirzepatide for weight loss is through Zepbound.

We have a full Zepbound vs Wegovy comparison with the head-to-head data, current pricing, and which one tends to win for which kind of reader.

If you’re comparing these medications specifically for PCOS, use our Mounjaro vs Wegovy for PCOS guide instead — the decision factors are different.

What real searchers say (voice of customer)

Below is real attributable language from public forums showing the most common frustration we see across “Mounjaro vs Wegovy” searches: insurance and coupons that don’t line up with diagnosis. We’re sharing this as voice-of-customer to show what readers are actually wrestling with — not as medical or pricing evidence.

“My insurance doesn’t cover Wegovy so it would cost me over $1,300 a month where Mounjaro would be $25. I don’t have diabetes.”
— Reddit user in r/Mounjaro, describing insurance/coupon confusion. Used here as voice-of-customer language, not medical or pricing evidence. Source: r/Mounjaro thread, “Approved for Wegovy but Mounjaro is affordable.”

That tension — the cheaper drug isn’t the on-label drug, the on-label drug isn’t covered — is the single most common pattern in this category. It’s why this entire page exists. The right answer for that reader is almost never “use the cheaper off-label option.” It’s “check whether Zepbound or Wegovy is actually covered, and use the on-label match.” That’s also why we lean toward routing readers to a free coverage check before they pay cash.

How to decide in 5 minutes: the Mounjaro vs Wegovy path finder

Use this as a rough guide. It doesn’t replace your clinician’s judgment.

If you’re still stuck after this, that’s exactly what our free 60-second GLP-1 path quiz is built for.

What we actually verified

This is the box every commercial page on this site has — what we checked, where, and when. If something is missing from this list, we couldn’t independently verify it.

Affiliate disclosure: The RX Index may earn a commission if you use some links on this page to start a telehealth program. Our editorial recommendations are based on FDA labeling, current verified pricing, clinical evidence, and reader fit. Affiliate relationships do not change which medication or provider we recommend for a given situation.

Frequently asked questions

Bottom line: the one-question test

We’ve covered a lot. Here’s the cleanest way to act on it.

If you have type 2 diabetes: ask your endocrinologist or primary care doctor about Mounjaro. Don’t make this decision from a comparison article.

If you don’t have diabetes and you want weight loss: the right medication is Wegovy or Zepbound — not Mounjaro. The right brand depends on your insurance, your tolerance, your needle preference, and whether you have any of the conditions Wegovy specifically addresses (cardiovascular disease, MASH, adolescent obesity).

If you’re paying cash and want a low FDA-approved branded starting price: Wegovy pill ($149/month for 1.5 mg or 4 mg) is among the cheapest as of May 2, 2026. Wegovy injection ($199 intro, then $349/month) is next. Zepbound KwikPen ($299–$449/month) comes after.

If insurance is the question: check coverage before paying cash. Ro’s free GLP-1 Insurance Coverage Checker takes about 5 minutes and tells you exactly what your plan will and won’t cover for Wegovy, Zepbound, and Ozempic. They’ll also handle prior authorization paperwork at no extra cost if you decide to move forward.

This page is editorial guidance from The RX Index, a pricing intelligence and comparison resource for GLP-1 telehealth providers. It is not medical advice and does not replace a licensed clinician’s judgment. We update commercial pricing monthly and full medical content quarterly. Last verified May 2, 2026.

Sources

1. DailyMed. “MOUNJARO (tirzepatide) injection prescribing information.” dailymed.nlm.nih.gov. FDA-approved indication: type 2 diabetes, ages 10+.
2. DailyMed. “WEGOVY (semaglutide) injection prescribing information” and Wegovy tablet prescribing information. dailymed.nlm.nih.gov. Indications: chronic weight management; MACE risk reduction in CVD + obesity; noncirrhotic MASH with moderate-to-advanced fibrosis (injection only, accelerated approval).
3. Aronne LJ et al. “Tirzepatide vs Semaglutide for Treatment of Obesity.” N Engl J Med, May 2025. SURMOUNT-5. 20.2% vs 13.7% mean weight loss at 72 weeks.
4. Eli Lilly. “Mounjaro Cost Information.” pricinginfo.lilly.com/mounjaro. List price: $1,112.16 per 28-day fill.
5. Lilly. Mounjaro Savings Card. startlilly.com/mounjaro. Terms: commercial insurance + FDA-approved use; $25 covered, $499 uncovered.
6. NovoCare. Wegovy self-pay pricing. novocare.com. Wegovy pill $149/$299, injection $199 intro/$349 standard, Wegovy HD $399.
7. LillyDirect. lilly.com/lillydirect. Zepbound KwikPen $299–$449/month.
8. Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” (SELECT). N Engl J Med, November 2023. nejm.org.
9. Rodriguez PJ et al. “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.” JAMA Internal Medicine, 2024.
10. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge guidance (effective July 1, 2026 – December 31, 2027). cms.gov. Foundayo, Wegovy injection, Wegovy tablets, Zepbound KwikPen eligible; Mounjaro not eligible.
11. U.S. Food and Drug Administration. Wegovy MASH accelerated approval (Aug 2025); Wegovy pill approval (Dec 2025); Wegovy HD 7.2 mg approval (Mar 2026); Foundayo (orforglipron) approval (Apr 1, 2026). fda.gov.
12. European Medicines Agency PRAC, June 2025. NAION conclusion for semaglutide medicines. ema.europa.eu.
13. Ro. “Weight Loss Program Pricing.” ro.co/weight-loss/pricing. Ro Body $39 first month, $149/month, $74/month annual prepay.
14. Ro. “GLP-1 Insurance Coverage Checker.” ro.co/weight-loss/glp1-insurance-checker.
15. Sesame Care. “Online Weight Loss Program.” sesamecare.com/service/online-weight-loss-program. Branded GLP-1 options including Wegovy pill/pen, Zepbound KwikPen, Zepbound vial, Foundayo, Ozempic; care from $59/month with annual subscription.
16. Reddit r/Mounjaro. Voice-of-customer thread on insurance/coupon confusion. reddit.com/r/Mounjaro. Used as voice-of-customer language only, not medical or pricing evidence.